|
Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
|
|
Consulting or Advisory Role - Merck; Novartis; Pfizer; Roche |
Speakers' Bureau - MSD; Novartis; Roche |
Research Funding - Abbvie (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Janssen; Sanofi |
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst) |
|
Alfredo Rodríguez Antolín |
Consulting or Advisory Role - Astellas Medivation; Bayer; Janssen |
Speakers' Bureau - Astellas Medivation; Janssen |
Travel, Accommodations, Expenses - Astellas Medivation; IPSEN |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; IPSEN; Roche |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst) |